2007 Life Sciences Compensation Findings Disclosed www.com...( BOSTON Nov. 27 /- J. Robert Scott...),Health

BOSTON, Nov. 27 /PRNewswire/ -- J. Robert Scott, a leading retainer-based executive search firm; Ernst & Young, a global leader in professional services; and the internationally recognized law firm of WilmerHale; in collaboration with professors from Harvard Business School, have released data for their 2007 Compensation & Entrepreneurship Report in Life Sciences, available at http://www.compstudy.com. This study is a valuable tool in helping businesses and executives understand today's ever-changing compensation trends for senior executives within privately-held therapeutic, diagnostic, medical device, instrumentation and platform companies.

"Being aware of changing compensation trends allows businesses to understand the executive talent pool and to better align their compensation strategies and programs with current market conditions," commented J. Robert Scott Managing Director Bruce Rychlik. "The compensation study includes significant data on cash compensation, equity holdings, base salaries and bonuses. In the past, reliable equity and cash compensation figures have only been available for public biotechnology companies. Compstudy.com provides much-needed statistics on the changing dynamics for senior executives within private, venture-backed life science companies."

Five key findings were identified in this year's survey:

-- Salary and Bonus: Total target cash for the CEO rose 2% year over year,

most notably in base salary, an increase of $11,000. Average base

salary rose by 5.9% across the executive positions surveyed from 2006

to 2007. Average target bonus remained largely unchanged year over

year.

-- Equity Holdings: Option grants continue to dominate as vehicles used

for the executive team. Incentive stock options account for just over

half of the equity grants to the management team in 2007, down from 62%'/>"/>